// App-Quantinova.ai

: Efficacy Responses Across Disease Severity and Treatment History Subgroups of Patients With Moderate to Severe Plaque Psoriasis Treated With Guselkumab: Pooled Results From VOYAGE 1&2 Through 5 Years

Researchers

Presenter

  • Kenneth B. Gordon

Principal Investigators

  • Joseph F. Merola

  • Peter Foley

  • Olivia Choi

  • Daphne Chan

  • Megan Miller

  • Yin You

  • Yaung-Kaung Shen

  • Ya-Wen Yang

  • Andrew Blauvelt

Medical Centers

  • The Medical College of Wisconsin, Milwaukee, WI

  • Harvard Medical School, Brigham and Women's Hospital, Boston, MA.

  • The University of Melbourne, St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute, Department of Medicine, Carlton, Australia

  • Janssen Scientific Affairs, Horsham, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Oregon Medical Research Center, Portland, OR, USA, Portland, OR

Locations

  • United States

  • Australia

  • Maldives

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved